Quarterly report pursuant to Section 13 or 15(d)

Subsequent Events (Details Narrative)

v3.20.2
Subsequent Events (Details Narrative) - USD ($)
Oct. 06, 2020
Aug. 19, 2020
License Agreement [Member] | Yuhan Corporation [Member]    
Number of common stock issued during period   250,000
Price per share   $ 8.00
Subsequent Event [Member] | Restricted Stock Award [Member]    
Number of stock awards vested in period 214,078  
Subsequent Event [Member] | License Agreement [Member] | Aposense, Ltd. [Member]    
Number of common stock issued during period 625,000  
Price per share $ 4.00  
Subsequent Event [Member] | License Agreement [Member] | Elion Oncology, Inc. [Member]    
Number of common stock issued during period 825,000  
Price per share $ 4.00  
Payment for license grant $ 100,000  
Subsequent Event [Member] | License Agreement [Member] | Yuhan Corporation [Member]    
Number of common stock issued during period 250,000  
Price per share $ 4.00  
Public Offering [Member] | Subsequent Event [Member]    
Number of common stock issued during period 4,800,000  
Price per share $ 4.00  
Proceeds from offering $ 17,100,000  
Public Offering [Member] | Subsequent Event [Member] | Anti-Dilution Provision [Member]    
Number of common stock issued during period 1,156,480  
Underwritten Public Offering [Member] | License Agreement [Member] | Yuhan Corporation [Member]    
Number of common stock issued during period   750,000
Proceeds from offering   $ 3,000,000
Underwritten Public Offering [Member] | Subsequent Event [Member]    
Number of common stock issued during period 4,800,000  
Price per share $ 4  
Proceeds from offering $ 17,100,000  
Number of stock awards vested in period 214,078  
Underwritten Public Offering [Member] | Subsequent Event [Member] | LOC Agreements [Member] | DKBK Enterprises, LLC [Member]    
Debt conversion principal amount and related interest $ 700,000  
Debt conversion into shares 199,537